MENU
+Compare
IBRX
Stock ticker: NASDAQ
AS OF
Nov 13, 04:59 PM (EDT)
Price
$2.00
Change
-$0.06 (-2.91%)
Capitalization
1.97B

IBRX ImmunityBio Forecast, Technical & Fundamental Analysis

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response... Show more

Industry: #Biotechnology
IBRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for IBRX with price predictions
Nov 12, 2025

IBRX in downward trend: 10-day moving average broke below 50-day moving average on October 13, 2025

The 10-day moving average for IBRX crossed bearishly below the 50-day moving average on October 13, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 03, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 30, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .

IBRX moved below its 50-day moving average on October 29, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for IBRX entered a downward trend on November 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IBRX's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in of 242 cases, the price rose further within the following month. The odds of a continued upward trend are .

IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (24.439). P/E Ratio (0.000) is within average values for comparable stocks, (63.753). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.001). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (20.747) is also within normal values, averaging (322.723).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IBRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
IBRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

IBRX is expected to report earnings to rise 63.29% to -11 cents per share on March 03

ImmunityBio IBRX Stock Earnings Reports
Q4'25
Est.
$-0.11
Q3'25
Beat
by $0.04
Q2'25
Beat
by $0.01
Q1'25
Missed
by $0.02
Q4'24
Beat
by $0.08
The last earnings report on November 05 showed earnings per share of -7 cents, beating the estimate of -10 cents. With 9.23M shares outstanding, the current market capitalization sits at 1.97B.
A.I. Advisor
published General Information

General Information

a producer of cancer treatment products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3530 John Hopkins Court
Phone
+1 844 696-5235
Employees
628
Web
https://www.immunitybio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BCAIX38.420.36
+0.95%
Boston Common ESG Impact Intl
TEMFX9.630.05
+0.52%
Templeton Foreign A
TOLSX16.890.05
+0.30%
DWS RREEF Global Infrastructure S
DOXBX13.910.01
+0.07%
Dodge & Cox Balanced X
HRLIX9.87N/A
N/A
Hartford Real Asset I

IBRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
-3.74%
AXON - IBRX
48%
Loosely correlated
-0.47%
CLRB - IBRX
45%
Loosely correlated
-1.69%
VRDN - IBRX
42%
Loosely correlated
+1.79%
RXRX - IBRX
42%
Loosely correlated
-1.27%
ARRY - IBRX
41%
Loosely correlated
-8.69%
More